Synerkine Pharma

Over Synerkine Pharma

Synerkine Pharma B.V. focuses on development of novel fusion proteins, called Synerkines, that combine the immunoregulatory activity of different cytokines. These fusion proteins have unique benefits over the individual cytokines and modulate a broad number of targets, including key elements in the pain pathway. This provides treatment options for chronic pain conditions with a clearly differentiated mechanism of action over current analgesic drugs and holds tremendous therapeutic and commercial potential. Synerkine Pharma B.V. was founded in 2018 as a spin-off of the University Medical Center Utrecht (UMCU), the Netherlands.

Adres

• Hoofdkantoor

  Galileiweg 82333BD LeidenZuid-Holland, Nederland

Team per functiegebied

Gebaseerd op 4 openbare functieprofielen, stand van 3 september 2026.

• Executive / C-Suite2
• Legal / Compliance1
• Research / R&D1